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Like two sides of the same coin, nanotechnology can be both boon and bane for respiratory medicine. Nanomaterials
open new ways in diagnostics and treatment of lung diseases. Nanoparticle based drug delivery systems can help
against diseases such as lung cancer, tuberculosis, and pulmonary fibrosis. Moreover, nanoparticles can be loaded
with DNA and act as vectors for gene therapy in diseases like cystic fibrosis. Even lung diagnostics with computer
tomography (CT) or magnetic resonance imaging (MRI) profits from new nanoparticle based contrast agents. However,
the risks of nanotechnology also have to be taken into consideration as engineered nanomaterials resemble natural
fine dusts and fibers, which are known to be harmful for the respiratory system in many cases. Recent studies have
shown that nanoparticles in the respiratory tract can influence the immune system, can create oxidative stress and
even cause genotoxicity. Another important aspect to assess the safety of nanotechnology based products is the
absorption of nanoparticles. It was demonstrated that the amount of pulmonary nanoparticle uptake not only depends
on physical and chemical nanoparticle characteristics but also on the health status of the organism. The huge diversity
in nanotechnology could revolutionize medicine but makes safety assessment a challenging task.
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Over the past years nanomaterials have found their way
into more and more areas of life. Examples are new
coatings and pigments, electronic devices as well as cos-
metic products like sunscreens and toothpastes. On top
of that, much effort is done to adopt nanotechnology for
the treatment of human diseases. The term “Nano” re-
fers to structures in the range of 1 to 100 nm. In con-
trast to nanoparticles, which have to measure between 1
and 100 nm in all dimensions, nanomaterials may consist
of elements bigger than 100 nm but need to be structured
in the nanoscale and exhibit characteristic features associ-
ated with their nanostructure [1]. In this context, the
International Organization for Standardization defined the
term nano-object as a material with one, two or three ex-
ternal dimensions in the nanoscale [2] (Fig. 1). Nanoma-
terials have an extremely high surface area to volume
ratio. Therefore, some of them are very reactive or* Correspondence: Thai.Dinh@uniklinikum-saarland.de
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effects become visible and lead to some of the unique
properties of nanoparticles. Like viruses and cellular struc-
tures, some nanoparticles are able to self-assemble to
more complex structures [3]. This makes them interesting
candidates for novel drugs. On the other hand it is neces-
sary to redefine toxicology because of nanotechnology.
Unlike classical toxicology, where dose and composition
matter, in nanotoxicology the focus has to be set on prop-
erties like morphology, size, size distribution, surface
charge, and agglomeration state as well. Nanotechnology
is important for respiratory medicine for several reasons.
Firstly, it offers new approaches to treat diseases of the re-
spiratory tract. However, as nanotechnology usage in con-
sumer products, cosmetics, and medicine is continuously
increasing, it is also pivotal to understand potentially ad-
verse effects of nanomaterials on the respiratory system.
Additionally, studying respiratory effects of manufactured
nanomaterials helps to understand the impact of combus-
tion exhaust and ultra-fine dusts on human health. On
top of that, the lung is probably the most important gate-
way of nanoparticles to the human organism. For the as-
sessment of safety in nanotechnology it is therefore also
important to elucidate which nanoparticle properties de-
termine pulmonary resorption and biodistribution (Fig. 2).ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Nano-Objects can be divided into nanoparticles, nanofibres and nanoplates depending on the number of external dimensions in the nanoscale
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diagnostics
Although clinical application of nanotechnology in ther-
apeutics and diagnostics is still rare, there are multiple
promising candidates for future use in the field of re-
spiratory medicine.Fig. 2 The increasing use of nanotechnology affects respiratory medicine i
options in therapy and diagnostics. Secondly, the use of nanomaterials can
with the use of nanomaterials are not fully understood and merit further in
inhaled nanoparticles on extrapulmonary organsDrug delivery
Nanoparticles can act as vessels for drugs because they
are small enough to reach almost any region of the hu-
man organism. Drugs can be bound chemically to the
nanoparticles by a multitude of different linker mole-
cules or by encapsulation. This allows better control ofn three main areas. Firstly, nanotechnology enables more sophisticated
cause toxic effects in the respiratory system. Health risks associated
vestigation. Moreover, it will be essential to understand the effects of
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ability of targeted drug delivery. The targeting can be ac-
tive or passive. In case of tumor diseases, the leaky and
immature vasculature of fast growing tumors can be
taken advantage of in order to achieve passive targeting
of chemotherapeutic loaded nanoparticles. This is called
the enhanced permeability and retention (EPR) effect
[4]. The first generation nano drug delivery systems rely
entirely on the EPR effect. One example is Genoxol-PM,
a polymeric paclitaxel loaded poly(lactic acid)-block-
poly(ethylene glycol) micelle-formulation [5]. This nanocar-
rier has recently been tested in a phase II trial in patients
with advanced non-small cell lung cancer (NSCLC). 43 pa-
tients were treated with four 3-week cycles of Genexol-PM
at 230 mg/m2 on day 1 combined with gemcitabine
1000 mg/m2 on day 1 and day 8. With a response rate of
46.5 %, the therapy showed favorable antitumor activity.
Moreover, emetogenicity was low. However, frequent grade
3/4 adverse events like neutropenia and pneumonia were
observed [6]. The second generation nanoparticle drug
delivery systems possess targeting ligands. These can be
antibodies, aptamers, small molecules and proteins
(Fig. 3). The attached ligands actively guide the nano-
particles and therefore the drugs to the tumor cells.
Tumor specific monoclonal antibodies are already
widely used in cancer therapy. Those antibodies can be
attached to nanoparticles for active targeting. In a re-
cent study polyglycolic acid nanoparticles, that wereFig. 3 Four different strategies for active targeting of nanoparticle based d
with tumor specific antibodies or aptamers. Additionally, small molecules, s
targeting receptors that are overexpressed on tumorsconjugated with cetuximab antibodies for targeting and
loaded with the drug paclitaxel palmitate, were admin-
istered intravenously to mice with A549-luc-C8 lung
tumors. The survival rate of these mice increased sig-
nificantly compared to the control group [7]. Another
approach involves aptamers as targeting agents. Apta-
mers are synthetic oligonucleotides that are capable of
binding specific target structures. Their small size, their
simple synthesis, and their lack of immunogenicity
make them promising ligands for nanoparticles. More-
over, small molecules such as folate can be used for tar-
geting tumor cells that express a high density of folate
receptors. In addition, tumors often overexpress recep-
tors for several proteins. Proteins like transferrin there-
fore are common targeting ligands [8]. These second
generation nanocarriers are already used clinically
against lung cancer with substances like Aurimmune
Cyt-6091 and Bind-014. Aurimmune Cyt-6091 is a drug
delivery system based on gold nanoparticles functional-
ized with polyethylene glycol (PEG) and tumor necrosis
factor alpha (TNF-α). It has been used against adeno-
carcinoma of the lung in a phase I clinical trial. The
TNF-α serves both as targeting and therapeutic agent
in this case [9]. A phase II clinical trial for non-small
cell lung cancer patients has been planned [10]. The
nano drug delivery system Bind-014 is currently tested
in a phase II clinical trial as second-line therapy for pa-
tients with non-small cell lung cancer [11]. Bind-014rug delivery systems are shown. The nanoparticles can be conjugated
uch as folate, as well as proteins, such as transferrin, can be used for
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which the anti-tumor drug docetaxel is physically en-
trapped. The particles are surface-decorated with PEG
to reduce elimination from the immune system and
contain ligands against prostate-specific membrane
antigen (PSMA) for targeting. PSMA is expressed in
prostate cancer cells and in the neovasculature of non-
prostate solid tumors, such as NSCLC [12]. Preliminary
data demonstrates, that Bind-014 is clinically active and
well tolerated. It also showed promising effects on patients
with KRAS mutations, where ordinary anti-tumor agents
usually fail. Additionally, adverse effects like anemia, neu-
tropenia and neuropathy were significantly reduced com-
pared to solvent based docetaxel [13].
Nanoparticle based drug delivery also offers potential
in other fields of respiratory medicine. In experiments
with tuberculosis infected guinea pigs, it was demon-
strated that inhaled alginate nanoparticles encapsulating
isoniazid, rifampicin, and pyrazinamide showed better
bioavailability and higher efficiency than oral drug medi-
cation [14]. Similar results were presented by Pandey
et al. with the three antitubercular drugs encapsulated in
poly (DL-lactide-co-glycolide) nanoparticles [15]. More-
over, another study demonstrated that pirfenidone
loaded nanoparticles have higher anti-fibrotic efficacy in
the treatment of mice with bleomycin-induced pulmon-
ary fibrosis than dissolved pirfenidone [16].Fig. 4 Two different approaches of nanoparticle based hyperthermia thera
(MNP) are applied intravenously and accumulate inside the tumor. When a
magnetic nanoparticles produce heat inside the tumor. b In photothermal
nanoparticles are applied intravenously and accumulate inside the tumor. U
gold nanoshells convert the laser light into heatHyperthermia
Nanoparticle induced hyperthermia can be used to lo-
cally destroy tumor cells. Heat generation is usually
achieved by two approaches, magnetic and photothermal
hyperthermia. In magnetic hyperthermia, an extracor-
poreal coil creates an alternating magnetic field that
heats magnetic nanoparticles inside a tumor. This in-
creases the temperature in the tumor without affecting
healthy tissue. A recent study assessed the effect of
inhalable superparamagnetic iron oxide nanoparticles in
a mouse model of NSCLC. Compared to the non-
targeted nanoparticles, the epidermal growth factor re-
ceptor (EGFR) targeted nanoparticles showed significantly
more effective tumor shrinkage after magnetic hyperther-
mia treatment [17]. The other approach, photothermal
therapy uses laser radiation in the visible or near infrared
spectrum and photosensitizing nanoparticles such as gold
or graphene. A commercial product called auroshell is
available for tumor therapy. Auroshell nanoparticles con-
sist of a silica core surrounded by a thin layer of gold. The
gold nanoshells are administered intravenously and accu-
mulate in the tumor due to the EPR effect. Upon exposure
of the tumor to a near infrared laser, the laser energy is ef-
ficiently converted to heat by the gold nanoshells [18].
This therapy, which is called AuroLase, is currently under-
going clinical trial in patients with primary and/or meta-
static lung tumors [19] (Fig. 4).py are shown. a In magnetic hyperthermia, magnetic nanoparticles
n oscillating magnetic field is created by an extracorporeal coil the
hyperthermia, gold nanoshells (GNS) or similar photosensitizing
pon exposure of the tumor to near infrared (NIR) laser radiation, the
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Like viruses, nanoparticles can be used as vectors for
genes. But in contrast to viruses, they are less immuno-
genic and have higher DNA transport capacity. In a
study, DNA loaded polyethylenimine nanoparticles were
used in order to treat lipopolysaccharide induced acute
lung injury in mice. After intravenous injection of the
nanoparticles, the beta2-Adrenic Receptor genes in the
nanoparticles led to a short lived transgene expression in
alveolar epithelia cells. As a result the 5-day survival rate
improved from 28 % to 64 %. The severity of the symp-
toms measured by alveolar fluid clearance, lung water
content, histopathology, bronchioalveolar lavage cellular-
ity, protein concentration, and inflammatory cytokines
was also significantly attenuated [20]. DNA loaded nano-
particles are also promising candidates in the treatment
of cystic fibrosis. It was shown in a clinical trial that
nasal application of DNA nanoparticles is safe and evi-
dently leads to vector gene transfer [21]. One major
problem in this context is to overcome the mucus bar-
rier. In a recent study, it was demonstrated that densely
PEG-coated DNA nanoparticles can rapidly penetrate
extracorporeal human cystic fibrosis and extracorporeal
mouse airway mucus. In addition, those particles exhib-
ited better gene transfer after intranasal administration
to mice than conventional carriers [22].
Diagnostics
Nanoparticles have the potential to improve pulmonary
x-ray diagnostics. Folic acid-modified dendrimer-
entrapped gold nanoparticles were utilized as imaging
probes for targeted CT imaging. In in-vitro and in-vivo
tests, the nanoparticles were trapped in the lysosomes of
folic acid receptor expressing lung adenocarcinoma cells
(SPC-A1). It was possible to detect the tumor cells by
micro-CT imaging after nanoparticle uptake. In addition,
it was also shown that the particles possess good bio-
compatibility, with no impact on cell morphology, viability,
cell cycle, and apoptosis [23]. Nanoparticles can also be
used to enhance MR diagnostics of lung tissue. In experi-
ments with intratracheal administration of Gadolinium-
DOTA nanoparticles in mice, signal enhancements in sev-
eral organs including the lung were measured with
ultrashort-echo-time-proton-MRI. The signal change over
time in the different organs demonstrated the passage of
the nanoparticles from the lung to the blood, then to the
kidneys, and finally to the bladder [24].
Toxicological aspects of nanomaterials
Toxic effects of nanoparticles are a major concern in
pulmonary medicine. Especially ultrafine particles of low
soluble, low toxic materials like titanium dioxide, carbon
black, and polystyrene are overall more toxic and inflam-
matory than fine particles of the same material. Thisapplies to both synthesized nanoparticles and natural
dusts [25]. For nano related toxicity multiple mecha-
nisms seem to be important. In the following, the inter-
action with the immune system, the creation of
oxidative stress, and toxic effects on the genome are
taken a closer look at. In order to correlate toxic effects
with nanoparticle properties, it is necessary to thor-
oughly characterize the selected nanoparticles prior to
administration.
Nanoparticle characterization
The most commonly used methods to characterize
nanoparticles for toxicology studies are transmission
electron microscopy (TEM) for size, morphology, and
agglomeration, dynamic light scattering (DLS) for the
size distribution of the particles, zeta potential measure-
ment for nanoparticle surface charge, and x-ray diffrac-
tion (XRD) for the particles’ crystal structure. In some
cases such as gold and silver nanoparticles, UV-vis spec-
troscopy can be used to determine size and size distribu-
tion due to a special size dependent optical activity [26].
Ideally, nanoparticle characterization is repeated after
administration as changes of the nanoparticles during
the application process are possible. In in-vitro experi-
ments, nanoparticles are usually applied by mixing with
cell culture medium. The dissolved components of the
medium, especially the ions, lead to agglomeration and
precipitation of many nanoparticles, causing significant
changes in their physicochemical properties. Similar ef-
fects are to be expected when nanoparticles come into
contact with surfactant or other biological fluids. It was
shown, that some nanoparticles tend to form protein
coronae in biological systems [27].
Effects on immune system and inflammation
Many nanoparticles possess properties that give them the
potential to influence the immune system. In this context,
nanoparticles’ ability to penetrate cellular boundaries, to es-
cape phagocytation by macrophages, to act as haptens, and
even to disturb the Th1/Th2 balance might be essential
[28]. For carbon black nanoparticles, a recent study investi-
gated the effects of inhalative exposure on mice with
bleomycin-induced pulmonary fibrosis. The analysis of hist-
ology as well as cytokine expression suggested that the
nanoparticles triggered an inhalation exacerbated lung
inflammation. The author concluded that especially for
people with pulmonary preconditions inhalation of nano-
particles can lead to serious health problems [29]. In this
context, another study found out that PEGylated cationic
shell-cross-linked knedel-like (cSCK) nanoparticles
produced significantly less airway inflammation than non-
PEGylated ones. This was explained by a change in endo-
cytosis. In contrast to the clathrin-dependent endocytosis of
non-PEGylated particles, the PEGylated cSCK nanoparticles
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hand, some nanomaterials exhibit impressive immune
modulating activity. As an example, [Gd@C82(OH)22]n, a
fullerene derivate with a gadolinium atom inside showed
anticancer activity without being cytotoxic (Fig. 5).
In vitro studies demonstrated that [Gd@C82(OH)22]n acti-
vated dendritic cells (DCs) and even induced phenotypic
maturation of those cells. Moreover, the [Gd@C82(OH)22]n
treated DCs also stimulated allogenic T cells in a Th1 char-
acteristic. The effect of [Gd@C82(OH)22]n was comparable,
probably even stronger than the effect of lipopolysacchar-
ide (LPS) on DCs. The study also verified that the nano-
particles were free of LPS contamination. In-vivo
experiments on ovalbumin (OVA) immunized mice
showed enhanced immune responses comparable to the
adjuvant effect of Alum on OVA mice. However, whereas
Alum lead to a Th2 response pattern with IL-4, IL-5 and
IL-10 upregulation, [Gd@C82(OH)22]n caused a Th1 pat-
tern with upregulation of IFNγ [31]. Similar results were
demonstrated in another study using a murine asthma
model. OVA sensitized mice that were additionally treated
with the nanomaterial graphene oxide during allergen
sensitization had stronger airway remodeling and hyperre-
sponsiveness than mice that have only been treated with
OVA. The graphene oxide lead to a downregulation of Th2
dependent markers such as IL-4, IL-5, IL-13 IgE and IgG1
but increased Th1-associated IgG2a. Moreover, the gra-
phene oxide increased the macrophage production of
mammalian chinitases, chitinase-3-like protein 1 (CHI3L1),
and AMCase, which could be the reason for the overallFig. 5 Gd@C82(OH)22 consists of a gadolinium atom (green) inside a
2 nm cage of carbon atoms (grey). The hydroxyl groups (red) outside
the cage are responsible for water solubility. In water the molecule
forms aggregates [Gd@C82(OH)22]n with average size of 25 nmaugmentation in airway remodeling and hyperresponsive-
ness [32]. However, this kind of immune modulation can
also be utilized for therapeutic purposes. In a recent study
a nanoparticle-based vaccine has been used to treat dust
mite allergies in mice. The immune-modulating carriers
were generated by loading dust mite allergen Der p2 and
the potent Th1 adjuvant unmethylated cytosine-
phosphate-guanine (CpG) into biodegradable poly(lactic-
co-glycolic acid) (PLGA) polymer particles. Mice treated
with those nanoparticles showed significantly lower airway
hyperresponsiveness as well as lower IgE antibody levels
after a 10 day intranasal Der p2 instillation compared to
the control group. The authors conclude that this bio-
degradable nanoparticle-based vaccination strategy has
significant potential for treating HDM allergies [33].
Oxidative stress and catalysis
Oxidative stress is often brought in context with nanotoxi-
cology. It can be measured directly with dichlorofluorecein
or indirectly by the upregulation of reactive oxygen species
(ROS) eliminating enzymes like superoxide dismutase [34].
Another approach involves tests whether the nanoparticle
dependent toxicity can be reduced by the application of an
antioxidant. Widely used semiconductor materials such as
lead sulfide nanoparticles may have the potential to gener-
ate oxidative stress in the lung. A recent study tested the
toxicity of intratracheally applied 30 nm and 60 nm lead
sulfide nanoparticles on rats. Oxidative damage was evalu-
ated based on superoxide dismutase, total antioxidant cap-
acity, and concentration of malondialdehyde. In addition to
inflammatory responses, both 30 nm and 60 nm groups
showed increased oxidative damage compared to control
groups. The effect was significantly stronger for the 30 nm
lead sulfide compared to the 60 nm nanoparticles [35]. An-
other nanomaterial which is associated with oxidative
stress is nanosized titanium dioxide. Li et al. induced pul-
monary injury in mice by daily intranasal instillation of sus-
pended 294 nm TiO2 nanoparticles for 90 days,
demonstrating that the rate of reactive oxygen species
(ROS) generation increased with increasing TiO2 doses.
Moreover lipid, protein and DNA peroxidation products
were identified in elevated doses, which suggests that ROS
dependent lung damage was significant in the nanoparticle
treated animals [36]. Furthermore, in vitro tests on BEAS-
2B and A549 lung cell lines demonstrated that the com-
monly used nanoparticles ZnO and Fe2O3 are very differ-
ent in terms of creating oxidative stress. The Fe2O3
nanoparticles with an average diameter of 39 nm were dis-
tributed in the cytoplasm, whereas the 63 nm ZnO nano-
particles were trapped in organelles such as the endosome.
In contrast to the Fe2O3 nanoparticles the ZnO nanoparti-
cles caused reactive oxygen species production as well as
cell cycle arrest, cell apoptosis, mitochondrial dysfunction
and glucose metabolism perturbation [37] (Table 1).
Table 1 Oxidative stress induction in respiratory tissue by different nanoparticles
Nanoparticles PbS PbS TiO2 ZnO Fe2O3
Size 60 nm 30 nm 294 nm 63 nm 39 nm
Model in vivo in vivo in vivo in vitro in vitro
(rat lungs) (rat lungs) (mice lungs) (BEAS-2B and A549 lung cells) (BEAS-2B and A549 lung cells)
Oxidative Stress + ++ + + -
Fig. 6 Pulmonary uptake of nanoparticles depends on size and
surface charge. Positively charged nanoparticles and nanoparticles that
are bigger than 34 nm cannot pass the epithelial barrier of the lung.
Only small and not positively charged nanoparticles can translocate
from the lung over blood and lymph system to the organism
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Another important type of toxicity caused by nanoparticles
is genotoxicity. A common method to quantify genotoxicity
is the comet assay, which uses electrophoresis to detect
DNA strand breaks. This assay was used in a recent study to
check whether intratracheal instilled fullerene C60 nanoparti-
cles induced DNA damage in male rats. However, despite in-
flammatory responses and hemorrhages in the alveoli of the
C60 treated rats, there was no significant increase in fractured
DNA in their lung cells. Therefore, it was concluded that
even at inflammation inducing doses, fullerene C60 nanopar-
ticles have no potential for DNA damage in the lung cells of
rats [38]. Similarly, another study demonstrated that intratra-
cheal instillation of anatase TiO2 nanoparticles on rats did
not result in genotoxicity. None of the TiO2 groups showed
an increase in fractured DNA while the positive control with
ethyl methanesulfonate exhibited significant increases [39].
In contrast to those results, Kyjovska ZO et al. found that
even in low doses, where no inflammation occurs, Printex
90 carbon black nanoparticles induce genotoxicity in mice.
There was no inflammation, cell damage and acute phase re-
sponse, which means that the increased DNA strand breaks
are related to direct DNA damage caused by the nanoparti-
cles [40]. On the other hand, a recent study suggests that
CeO2 nanoparticles may be even used as antioxidant and
anti-genotoxic agents in the lung. After treatment with the
oxidative stress-inducing agent KBrO3, BEAS-2B cells pre-
treated with the CeO2 nanoparticles showed significantly less
intracellular ROS as well as a reduction in DNA damage
compared to non-pretreated cells [41].
Biodistribution
Nanoparticle detection
Research on the biodistribution of nanoparticles requires
tracking of the applied nanoparticles in the test animal. Con-
ventional light microscopy is not able to detect nanoparticles
because of Abbe’s law. Therefore, electron microscopic im-
aging is often required. However, light microscopy can be
used to describe the nanoparticle induced changes in the
cell morphology without being able to see the nanoparticles
themselves. Additionally, nanoparticles can be indirectly
made detectable in light microscopy by a method called
autometallography. This is a silver staining that can be used
to increase the size of several types of nanoparticles like
gold, silver, and some metal sulfides and selenides in the
histological section [42]. This technique was used to detectsilver nanoparticles in the olfactory bulb and lateral brain
ventricles of mice that had been intranasally treated with
25 nm silver nanoparticles [43].
Particle deposition and resorption in the respiratory tract
Most research about biodistribution of nanoparticles in or-
ganisms focuses on intravenous injection. However, nano-
particles were shown to be able to pass the blood air barrier
of the lung. Whether or not nanoparticles can travel through
the lung into the body seems to be size dependent. This was
evaluated by injecting neutron activated radioactive gold
nanoparticles of 1.4 nm and 18 nm intratracheally to rats.
The bigger nanoparticles almost completely retained in the
lung while significant amounts of the smaller 1.4 nm parti-
cles were found in blood, liver, skin and carcass 24 h after
instillation [44]. Choi H. S. et al. applied nanoparticles of dif-
ferent size and charge to mice. The nanoparticles were
tracked in different organs through fluorescence labeling. It
was demonstrated that nanoparticles rapidly translocated to
the mediastinal lymph nodes if they possess a hydrodynamic
diameter of 34 nm or less and a neutral or anionic surface.
Bigger and positively charged nanoparticles exhibited no
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rameters of the applied nanoparticles the health status of
the exposed organism also seems to play an important
role. A recent study showed that the distribution of oro-
pharyngeal instilled 40 nm gold nanoparticles is influ-
enced by additional LPS treatment. The gold content of
organs was measured with inductively coupled plasma
mass spectroscopy. BALB/C mice that had been oropha-
ryngeal treated with LPS 24 h prior to the nanoparticle ad-
ministration exhibited less gold content in their lungs
than untreated mice. In both groups gold was detected in
different organs. High concentrations were found in heart
and thymus in the non LPS group, while the LPS treated
mice accumulated most of the gold in the spleen. The au-
thor concluded that nanoparticle uptake may depend on
medical preconditions [46].
Conclusions
Over the last decade, major breakthroughs in nanotech-
nology have been achieved. It is only a matter of time
before new nano based drugs reach respiratory medicine.
Especially the fields of targeted drug delivery, gene ther-
apy, and hyperthermia offer great potential for modern
drugs. On the other hand the increased use of nanoma-
terials in all fields of life also bears the risk of exposure
through inhalation. It is therefore essential to under-
stand pulmonary toxicology of nanomaterials in all its
facets. However, it is still very unclear why the toxic ef-
fects of nanoparticles in the respiratory tract are so in-
homogeneous and not well predictable. In this context,
not only local reactions of lung and airways but also
nanoparticle uptake and distribution in the organism are
important factors and therefore fields of current re-
search. As only few nanoparticle compositions have been
tested, it is questionable whether those results can be
easily adapted to other nanoparticles. Because of the
continuously increasing diversity of engineered nanopar-
ticles, toxicology can hardly keep pace with the safety as-
sessment of future products. Therefore, more attention
should be set on this wide field of research.
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